DE2653232C2 - - Google Patents

Info

Publication number
DE2653232C2
DE2653232C2 DE2653232A DE2653232A DE2653232C2 DE 2653232 C2 DE2653232 C2 DE 2653232C2 DE 2653232 A DE2653232 A DE 2653232A DE 2653232 A DE2653232 A DE 2653232A DE 2653232 C2 DE2653232 C2 DE 2653232C2
Authority
DE
Germany
Prior art keywords
wall
cellulose
cellulose acetate
liquid
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
DE2653232A
Other languages
German (de)
English (en)
Other versions
DE2653232A1 (de
Inventor
Felix Los Altos Calif. Us Theeuwes
Atul D. Belmont Calif. Us Ayer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alza Corp
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of DE2653232A1 publication Critical patent/DE2653232A1/de
Application granted granted Critical
Publication of DE2653232C2 publication Critical patent/DE2653232C2/de
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Reproductive Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Coating Apparatus (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
DE19762653232 1975-11-24 1976-11-23 Vorrichtung zur abgabe eines wirkstoffs durch osmose Granted DE2653232A1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US05/634,859 US4077407A (en) 1975-11-24 1975-11-24 Osmotic devices having composite walls

Publications (2)

Publication Number Publication Date
DE2653232A1 DE2653232A1 (de) 1977-06-08
DE2653232C2 true DE2653232C2 (enExample) 1989-08-24

Family

ID=24545453

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19762653232 Granted DE2653232A1 (de) 1975-11-24 1976-11-23 Vorrichtung zur abgabe eines wirkstoffs durch osmose

Country Status (20)

Country Link
US (2) US4077407A (enExample)
JP (1) JPS6058724B2 (enExample)
AR (1) AR216642A1 (enExample)
AT (1) AT356821B (enExample)
AU (1) AU506506B2 (enExample)
BE (1) BE848639A (enExample)
CA (1) CA1074653A (enExample)
CH (1) CH629957A5 (enExample)
DE (1) DE2653232A1 (enExample)
DK (1) DK150533C (enExample)
ES (1) ES453530A1 (enExample)
FR (1) FR2332008A1 (enExample)
GB (1) GB1528265A (enExample)
IE (1) IE44264B1 (enExample)
IL (1) IL50851A (enExample)
IT (1) IT1070481B (enExample)
MX (1) MX157537A (enExample)
NL (1) NL187298C (enExample)
SE (1) SE430301B (enExample)
ZA (1) ZA766900B (enExample)

Families Citing this family (495)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4077407A (en) * 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4445885A (en) * 1977-02-16 1984-05-01 Unitika, Ltd. Insulin releasing supplier
US4519909A (en) * 1977-07-11 1985-05-28 Akzona Incorporated Microporous products
US4159720A (en) * 1977-11-28 1979-07-03 Burton Andrew F Infusion of liquids into tissue
US4304672A (en) * 1978-04-04 1981-12-08 Sbr Lab, Inc. Stored blood and liquid system pH control method and apparatus
NZ192673A (en) * 1979-02-02 1984-07-06 Merck & Co Inc Ophthalmic compositions for lowering intraocular pressure
US4235236A (en) * 1979-02-12 1980-11-25 Alza Corporation Device for dispensing drug by combined diffusional and osmotic operations
US4357236A (en) * 1979-05-17 1982-11-02 Borg-Warner Corporation Automatic addition of a corrosion inhibitor to a coolant system by osmotic pressure
ATE9059T1 (de) * 1980-01-28 1984-09-15 Merck & Co. Inc. Ophthalmische kohlensaure anhydrase-inhibitoren enthaltende einlagen zur verringerung intraokularer hypertension.
IE50901B1 (en) * 1980-03-04 1986-08-06 Merck & Co Inc Ophthalmic compositions of carbonic anhydrase inhibitors for topical application in the treatment of elevated intraocular pressure
JPS57140710A (en) * 1981-02-24 1982-08-31 Shionogi & Co Ltd Capsule agent for rectal administration
JPH0245604B2 (enExample) * 1980-07-09 1990-10-11 Yunibaashitei Obu Furorida Za
US4300558A (en) * 1980-07-18 1981-11-17 Alza Corporation Self-driven fluid dispenser
US4439195A (en) * 1980-10-14 1984-03-27 Alza Corporation Theophylline therapy
US4364385A (en) * 1981-03-13 1982-12-21 Lossef Steven V Insulin delivery device
USD271623S (en) 1981-04-27 1983-11-29 Eli Lilly And Company Animal capsule
US4484921A (en) * 1982-02-01 1984-11-27 Alza Corporation Theophylline therapy utilizing osmotic delivery
JPS5931701A (ja) * 1982-08-16 1984-02-20 Nitto Electric Ind Co Ltd 液状活性物質含有膜及びその製造方法
US4443428A (en) * 1982-06-21 1984-04-17 Euroceltique, S.A. Extended action controlled release compositions
US4478596A (en) * 1982-11-26 1984-10-23 Michelson Paul E Delivery system for physiologically active agents
US4613330A (en) * 1982-11-26 1986-09-23 Michelson Paul E Delivery system for desired agents
IE53703B1 (en) * 1982-12-13 1989-01-18 Elan Corp Plc Drug delivery device
US4585792A (en) * 1983-05-05 1986-04-29 Technology Unlimited Inc. Protective additive to vaginal products and catamenials
US4722936A (en) * 1983-05-05 1988-02-02 Joseph Jacob Deodorization vaginal products and catamenials
US4722937A (en) * 1984-06-29 1988-02-02 Joseph Jacob Antitoxin vaginal products and catamenials
US5082668A (en) * 1983-05-11 1992-01-21 Alza Corporation Controlled-release system with constant pushing source
US4765989A (en) * 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US4783337A (en) * 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US4503030A (en) * 1983-06-06 1985-03-05 Alza Corporation Device for delivering drug to certain pH environments
US4627850A (en) * 1983-11-02 1986-12-09 Alza Corporation Osmotic capsule
US4751071A (en) * 1983-12-01 1988-06-14 Alza Corporation Composition comprising salbutamol
US4777049A (en) * 1983-12-01 1988-10-11 Alza Corporation Constant release system with pulsed release
US4851229A (en) * 1983-12-01 1989-07-25 Alza Corporation Composition comprising a therapeutic agent and a modulating agent
GB2150830B (en) * 1983-12-05 1987-08-19 Alza Corp Drug dispenser
US4761159A (en) * 1984-01-23 1988-08-02 Lewis Knox Method of chemical deodorization of articles and solutions used in medical and biological procedures
US4729793A (en) * 1985-08-09 1988-03-08 Alza Corporation Composition for manufacturing wall of dispensing device
US4800056A (en) * 1984-03-21 1989-01-24 Alza Corporation Process for making dispenser with cooperating elements
US4716031A (en) * 1984-03-21 1987-12-29 Alza Corporation Drug dispenser comprising a multiplicity of members acting together for successfully dispensing drug
US4814180A (en) * 1984-03-21 1989-03-21 Alza Corporation Agent dispenser comprising a semipermeable wall surrounding single-piece or two-piece container
US4663148A (en) * 1984-03-21 1987-05-05 Alza Corporation Dispenser comprising telescopically engaging members
US4663149A (en) * 1984-03-21 1987-05-05 Alza Corporation Dispenser comprising inner and outer walls functioning as cooperative unit
US4692326A (en) * 1984-03-21 1987-09-08 Alza Corporation Dispenser comprising inner positioned soft or hard capsule
US4615698A (en) * 1984-03-23 1986-10-07 Alza Corporation Total agent osmotic delivery system
US4649075A (en) * 1984-08-09 1987-03-10 Leonora Jost Transdermal and transmucosal vortexed foam devices and the method of making
US4743247A (en) * 1984-08-13 1988-05-10 Alza Corporation Process for manufacturing dosage form
GB8422876D0 (en) * 1984-09-11 1984-10-17 Secr Defence Silicon implant devices
US4693886A (en) * 1985-04-22 1987-09-15 Alza Corporation Osmotic device with inert core
US4609374A (en) * 1985-04-22 1986-09-02 Alza Corporation Osmotic device comprising means for governing initial time of agent release therefrom
US4655766A (en) * 1985-08-01 1987-04-07 Alza Corporation Fluid imbibing pump with self-regulating skin patch
US4756314A (en) * 1985-10-28 1988-07-12 Alza Corporation Sweat collection patch
US5204339A (en) * 1986-01-31 1993-04-20 Whitby Research, Inc. Penetration enhancers for transdermal delivery of systemic agents
ATE84667T1 (de) * 1986-01-31 1993-02-15 Whitby Research Inc Hautpenetration verbessernde zusammensetzungen.
US4747847A (en) * 1986-02-07 1988-05-31 Alza Corporation System for delivering potassium chloride with enhanced bioacceptability
US4971790A (en) * 1986-02-07 1990-11-20 Alza Corporation Dosage form for lessening irritation of mocusa
US4867969A (en) * 1986-02-07 1989-09-19 Alza Corporation Hydrogel formulation for administering non-steroidal drugs
US4927632A (en) * 1986-06-26 1990-05-22 Alza Corporation Selective pulsed drug delivery system
US4786500A (en) * 1986-06-26 1988-11-22 Alza Corporation Programmable agent delivery system
US4885868A (en) * 1986-12-03 1989-12-12 Cornell Research Foundation, Inc. Banding techniques for plant propagation
US4917688A (en) * 1987-01-14 1990-04-17 Nelson Research & Development Co. Bandage for transdermal delivery of systemically-active drug
US4832690A (en) * 1987-01-23 1989-05-23 Baxter International Inc. Needle-pierceable cartridge for drug delivery
US4801461A (en) * 1987-01-28 1989-01-31 Alza Corporation Pseudoephedrine dosage form
US4915952A (en) * 1987-02-27 1990-04-10 Alza Corporation Composition comprising drug, HPC, HPMC and PEO
US5023076A (en) * 1987-02-27 1991-06-11 Alza Corporation Lamina comprising carboxyvinyl polymer
US4731122A (en) * 1987-03-30 1988-03-15 Alza Corporation Process for manufacturing a thermoplastic molding composition
US5391381A (en) * 1987-06-25 1995-02-21 Alza Corporation Dispenser capable of delivering plurality of drug units
US5340590A (en) * 1987-06-25 1994-08-23 Alza Corporation Delivery system with bilayer osmotic engine
US5236689A (en) * 1987-06-25 1993-08-17 Alza Corporation Multi-unit delivery system
US4795641A (en) * 1987-08-20 1989-01-03 Eastman Kodak Company Polymer blends having reverse phase morphology for controlled delivery of bioactive agents
US4879275A (en) * 1987-09-30 1989-11-07 Nelson Research & Development Co. Penetration enhancers for transdermal delivery of systemic agent
US4920101A (en) * 1987-09-30 1990-04-24 Nelson Research & Development Co. Compositions comprising 1-oxo- or thiohydrocarbyl substituted azacycloaklkanes
US4906475A (en) * 1988-02-16 1990-03-06 Paco Pharmaceutical Services Estradiol transdermal delivery system
US4877618A (en) * 1988-03-18 1989-10-31 Reed Jr Fred D Transdermal drug delivery device
US4959218A (en) * 1988-03-25 1990-09-25 Alza Corporation Method for delivering somatotropin to an animal
US4855141A (en) * 1988-03-25 1989-08-08 Alza Corporation Device comprising means for protecting and dispensing fluid sensitive medicament
US4996060A (en) * 1988-03-25 1991-02-26 Alza Corporation Device comprising liner for protecting fluid sensitive medicament
US5006346A (en) * 1988-04-28 1991-04-09 Alza Corporation Delivery system
US5024842A (en) * 1988-04-28 1991-06-18 Alza Corporation Annealed coats
US4931285A (en) * 1988-04-28 1990-06-05 Alza Corporation Aqueous based pharmaceutical coating composition for dosage forms
US5160743A (en) * 1988-04-28 1992-11-03 Alza Corporation Annealed composition for pharmaceutically acceptable drug
GB8820353D0 (en) * 1988-08-26 1988-09-28 Staniforth J N Controlled release tablet
US5612059A (en) * 1988-08-30 1997-03-18 Pfizer Inc. Use of asymmetric membranes in delivery devices
US5037420A (en) * 1988-12-13 1991-08-06 Alza Corporation Delivery system comprising two sections for delivering somatotropin
US5135523A (en) * 1988-12-13 1992-08-04 Alza Corporation Delivery system for administering agent to ruminants and swine
US5057318A (en) * 1988-12-13 1991-10-15 Alza Corporation Delivery system for beneficial agent over a broad range of rates
US5059423A (en) * 1988-12-13 1991-10-22 Alza Corporation Delivery system comprising biocompatible beneficial agent formulation
US5174999A (en) * 1988-12-13 1992-12-29 Alza Corporation Delivery system comprising fluid ingress and drug egress
US5728088A (en) * 1988-12-13 1998-03-17 Alza Corporation Osmotic system for delivery of fluid-sensitive somatotropins to bovine animals
US5110596A (en) * 1988-12-13 1992-05-05 Alza Corporation Delivery system comprising means for delivering agent to livestock
US5034229A (en) 1988-12-13 1991-07-23 Alza Corporation Dispenser for increasing feed conversion of hog
US5030452A (en) * 1989-01-12 1991-07-09 Pfizer Inc. Dispensing devices powered by lyotropic liquid crystals
US5108756A (en) * 1989-01-12 1992-04-28 Pfizer Inc. Dispensing devices powered by lyotropic liquid crystals
IL92966A (en) * 1989-01-12 1995-07-31 Pfizer Dispensing devices powered by hydrogel
US5019396A (en) * 1989-05-12 1991-05-28 Alza Corporation Delivery dispenser for treating cardiac arrhythmias
US5273752A (en) * 1989-07-18 1993-12-28 Alza Corporation Controlled release dispenser comprising beneficial agent
US5126142A (en) * 1989-07-18 1992-06-30 Alza Corporation Dispenser comprising ionophore
US6361795B1 (en) * 1989-09-05 2002-03-26 Alza Corporation Method for lowering blood glucose
US5035897A (en) * 1989-09-05 1991-07-30 Alza Corporation Dosage form for delivering soluble or insoluble drugs
US5112614A (en) * 1989-09-14 1992-05-12 Alza Corporation Implantable delivery dispenser
US5200197A (en) * 1989-11-16 1993-04-06 Alza Corporation Contraceptive pill
US5098714A (en) * 1989-11-16 1992-03-24 Alza Corporation Osmotic, oral dosage form for fertility control
US5223266A (en) * 1990-01-24 1993-06-29 Alza Corporation Long-term delivery device with early startup
US5474785A (en) * 1990-01-24 1995-12-12 Alza Corporation Delivery system comprising means for controlling internal pressure
US5190763A (en) * 1990-05-07 1993-03-02 Alza Corporation Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
US5192550A (en) * 1990-05-07 1993-03-09 Alza Corporation Dosage form for treating central nervous system disorders
US5221536A (en) 1990-05-07 1993-06-22 Alza Corporation Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
US5238687A (en) * 1990-07-11 1993-08-24 Alza Corporation Delivery device with a protective sleeve
US5234694A (en) * 1990-07-11 1993-08-10 Alza Corporation Method for increasing feed efficiency in animals
US5234693A (en) * 1990-07-11 1993-08-10 Alza Corporation Delivery device with a protective sleeve
US5234692A (en) * 1990-07-11 1993-08-10 Alza Corporation Delivery device with a protective sleeve
US5180591A (en) * 1990-07-11 1993-01-19 Alza Corporation Delivery device with a protective sleeve
EP0542926B1 (en) * 1990-08-07 1995-02-15 Pfizer Inc. Use of interfacially-polymerized membranes in delivery devices
EP0550641B1 (en) * 1990-09-28 1994-05-25 Pfizer Inc. Dispensing device containing a hydrophobic medium
US5378475A (en) * 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
US6764697B1 (en) 1991-06-27 2004-07-20 Alza Corporation System for delaying drug delivery up to seven hours
US5178867A (en) * 1991-08-19 1993-01-12 Alza Corporation Dosage form for delivering drug in short-time period
US5240713A (en) * 1991-09-27 1993-08-31 Alza Corporation Dual rate agent delivery device
US5266332A (en) * 1991-12-06 1993-11-30 Alza Corporation Method for administering anti-Parkinson drug
US5254349A (en) * 1991-12-06 1993-10-19 Alza Corporation Process for lessening irritation caused by drug
US5200195A (en) * 1991-12-06 1993-04-06 Alza Corporation Process for improving dosage form delivery kinetics
US5200194A (en) * 1991-12-18 1993-04-06 Alza Corporation Oral osmotic device
IT1255522B (it) * 1992-09-24 1995-11-09 Ubaldo Conte Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita'
US5358721A (en) * 1992-12-04 1994-10-25 Alza Corporation Antiviral therapy
US6440457B1 (en) * 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
US6287598B1 (en) * 1993-05-28 2001-09-11 Alza Corporation Method for providing sustained antiepileptic therapy
US6080428A (en) * 1993-09-20 2000-06-27 Bova; David J. Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
US6129930A (en) * 1993-09-20 2000-10-10 Bova; David J. Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
US20060263428A1 (en) * 1993-09-20 2006-11-23 Eugenio Cefali Methods for treating hyperlipidemia with intermediate release nicotinic acid compositions having unique biopharmaceutical characteristics
US6818229B1 (en) 1993-09-20 2004-11-16 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia
US20080045573A1 (en) * 1993-09-20 2008-02-21 Bova David J Methods and Sustained Release Nicotinic Acid Compositions for Treating Hyperlipidemia
US6746691B2 (en) 1993-09-20 2004-06-08 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
US6676967B1 (en) 1993-09-20 2004-01-13 Kos Pharmaceuticals, Inc. Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
US6183778B1 (en) 1993-09-21 2001-02-06 Jagotec Ag Pharmaceutical tablet capable of liberating one or more drugs at different release rates
US5532003A (en) * 1994-01-18 1996-07-02 Alza Corporation Pentoxifylline therapy
US5773021A (en) * 1994-03-14 1998-06-30 Vetoquinol S.A. Bioadhesive ophthalmic insert
US5525279A (en) * 1994-04-04 1996-06-11 Sekisui Kagaku Kogyo K.K. Method of forming a granulocyte adsorbing carrier and granulocyte remover
ZA953078B (en) * 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies
US20040191314A1 (en) * 1994-04-28 2004-09-30 Frank Jao Antiepileptic dosage form and process for protecting antiepileptic drug
US5698224A (en) * 1994-06-27 1997-12-16 Alza Corporation Tacrine therapy
US5914131A (en) * 1994-07-07 1999-06-22 Alza Corporation Hydromorphone therapy
US5595759A (en) * 1994-11-10 1997-01-21 Alza Corporation Process for providing therapeutic composition
US5713852A (en) * 1995-06-07 1998-02-03 Alza Corporation Oral dosage and method for treating painful conditions of the oral cavity
US5690952A (en) * 1995-06-07 1997-11-25 Judy A. Magruder et al. Implantable system for delivery of fluid-sensitive agents to animals
IT1282576B1 (it) 1996-02-06 1998-03-31 Jagotec Ag Compressa farmaceutica atta a cedere la sostanza attiva in tempi successivi e predeterminabili
AUPN814496A0 (en) 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
IT1282650B1 (it) * 1996-02-19 1998-03-31 Jagotec Ag Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici
US7094422B2 (en) * 1996-02-19 2006-08-22 Acrux Dds Pty Ltd. Topical delivery of antifungal agents
ATE234129T1 (de) 1996-06-18 2003-03-15 Alza Corp Vorrichtung zur verbesserung der transdermalen verabreichung von medikamenten oder der abnahme von körperflüssigkeiten
US5800624A (en) * 1996-10-22 1998-09-01 University Of Notre Dame Membrane process for separating carbohydrates
US6361796B1 (en) * 1996-10-25 2002-03-26 Shire Laboratories, Inc. Soluble form osmotic dose delivery system
CA2269707C (en) * 1996-10-25 2005-08-16 Edward M. Rudnic Soluble form osmotic dose delivery system
US6110499A (en) * 1997-07-24 2000-08-29 Alza Corporation Phenytoin therapy
US5902598A (en) * 1997-08-28 1999-05-11 Control Delivery Systems, Inc. Sustained release drug delivery devices
US6514530B2 (en) 1997-09-09 2003-02-04 Alza Corporation Dosage form comprising means for changing drug delivery shape
IN186245B (enExample) 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
US20040062799A1 (en) * 1997-09-29 2004-04-01 Ayer Atul D. Therapeutic composition and delivery system for administering drug
ES2172944T3 (es) 1997-12-05 2002-10-01 Alza Corp Forma de dosificacion osmotica que comprende un primer y un segundo revestimiento.
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
WO1999032120A1 (en) * 1997-12-22 1999-07-01 Euro-Celtique, S.A. A method of preventing abuse of opioid dosage forms
UA55507C2 (uk) * 1997-12-22 2003-04-15 Еро-Селтік, С.А. Лікарська форма для перорального введення та спосіб запобігання зловживанню пероральною опіоїдною композицією
DK1041975T3 (da) * 1997-12-22 2002-11-04 Alza Corp Hastighedskontrollerende membraner til anordninger til kontrolleret indførsel af medikament
US8524277B2 (en) * 1998-03-06 2013-09-03 Alza Corporation Extended release dosage form
US6245357B1 (en) 1998-03-06 2001-06-12 Alza Corporation Extended release dosage form
US6099859A (en) * 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
US20010038855A1 (en) * 1998-06-05 2001-11-08 Desjardin Michael A. Dosage form for administering prescribed dose
US6099862A (en) * 1998-08-31 2000-08-08 Andrx Corporation Oral dosage form for the controlled release of a biguanide and sulfonylurea
US6551613B1 (en) * 1998-09-08 2003-04-22 Alza Corporation Dosage form comprising therapeutic formulation
US6174547B1 (en) * 1999-07-14 2001-01-16 Alza Corporation Dosage form comprising liquid formulation
GB9822854D0 (en) 1998-10-21 1998-12-16 Reckitt & Colmann Prod Ltd Improvements in or relating to organic compositions
HUP0104993A3 (en) * 1998-11-02 2003-02-28 Alza Corp Mountain View Method and device for controlled delivery of active agents
US6706282B1 (en) 1998-11-02 2004-03-16 Evangeline Cruz Controlled delivery of phenoxyethyl-substituted 1,2,4-triazolones
US6342249B1 (en) 1998-12-23 2002-01-29 Alza Corporation Controlled release liquid active agent formulation dosage forms
CA2360938C (en) * 1999-02-02 2008-01-08 Warren Oliver Haggard Controlled release composite
US20040121014A1 (en) * 1999-03-22 2004-06-24 Control Delivery Systems, Inc. Method for treating and/or preventing retinal diseases with sustained release corticosteroids
US6217895B1 (en) 1999-03-22 2001-04-17 Control Delivery Systems Method for treating and/or preventing retinal diseases with sustained release corticosteroids
US6319510B1 (en) 1999-04-20 2001-11-20 Alayne Yates Gum pad for delivery of medication to mucosal tissues
CO5210862A1 (es) 1999-09-15 2002-10-30 Alza Corp Formas de dosificacion y metodos para proporcionar efectiva terapia de reboxetina con dosificacion de una vez al dia
KR100738276B1 (ko) * 1999-12-09 2007-07-12 알자 코포레이션 항바이러스성 약제
US6464688B1 (en) 2000-02-15 2002-10-15 Microsolutions, Inc. Osmotic pump delivery system with flexible drug compartment
AR030557A1 (es) * 2000-04-14 2003-08-27 Jagotec Ag Una tableta en multicapa de liberacion controlada y metodo de tratamiento
US6375972B1 (en) 2000-04-26 2002-04-23 Control Delivery Systems, Inc. Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
USRE44145E1 (en) 2000-07-07 2013-04-09 A.V. Topchiev Institute Of Petrochemical Synthesis Preparation of hydrophilic pressure sensitive adhesives having optimized adhesive properties
EP2932964A1 (en) 2000-10-30 2015-10-21 Euro-Celtique S.A. Controlled release hydrocodone formulations
US20060034922A1 (en) * 2000-11-03 2006-02-16 Andrx Labs, Llc Controlled release metformin compositions
CA2427195C (en) 2000-11-03 2009-10-06 Andrx Corporation Controlled release metformin compositions
US6866866B1 (en) * 2000-11-03 2005-03-15 Andrx Labs, Llc Controlled release metformin compositions
US6790459B1 (en) 2000-11-03 2004-09-14 Andrx Labs, Llc Methods for treating diabetes via administration of controlled release metformin
US6632217B2 (en) 2001-04-19 2003-10-14 Microsolutions, Inc. Implantable osmotic pump
EP1390085B1 (en) * 2001-05-01 2009-08-05 A.V. Topchiev Institute of Petrochemical Synthesis Hydrogel compositions
AU2002316053A1 (en) 2001-05-01 2002-11-11 A.V. Topchiev Institute Of Petrochemical Synthesis Two-phase, water-absorbent bioadhesive composition
US8840918B2 (en) 2001-05-01 2014-09-23 A. V. Topchiev Institute of Petrochemical Synthesis, Russian Academy of Sciences Hydrogel compositions for tooth whitening
US20050113510A1 (en) 2001-05-01 2005-05-26 Feldstein Mikhail M. Method of preparing polymeric adhesive compositions utilizing the mechanism of interaction between the polymer components
US8541021B2 (en) 2001-05-01 2013-09-24 A.V. Topchiev Institute Of Petrochemical Synthesis Hydrogel compositions demonstrating phase separation on contact with aqueous media
US20050215727A1 (en) 2001-05-01 2005-09-29 Corium Water-absorbent adhesive compositions and associated methods of manufacture and use
US8206738B2 (en) 2001-05-01 2012-06-26 Corium International, Inc. Hydrogel compositions with an erodible backing member
UA81224C2 (uk) 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
CN1525851A (zh) 2001-05-11 2004-09-01 ������ҩ�����޹�˾ 抗滥用阿片样物质控释剂型
US7883717B2 (en) 2001-06-12 2011-02-08 Johns Hopkins University Reservoir device for intraocular drug delivery
IL159917A0 (en) 2001-07-18 2004-06-20 Euro Celtique Sa Pharmaceutical combinations of oxycodone and naloxone
AU2002324624A1 (en) 2001-08-06 2003-02-24 Euro-Celtique S.A. Sequestered antagonist formulations
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
HUP0401686A3 (en) * 2001-09-28 2008-04-28 Mcneil Ppc Inc Dosage forms having an inner core and outer shell with different shapes
US8101209B2 (en) * 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
EP1492509A1 (en) * 2001-12-18 2005-01-05 ALZA Corporation Dosage form providing time-varying patterns of drug delivery
JP2005513095A (ja) * 2001-12-19 2005-05-12 アルザ・コーポレーシヨン 治療剤の制御送達のための調合物＆投薬形態物
CA2471096A1 (en) * 2001-12-19 2003-07-03 Alza Corporation Formulation and dosage form for increasing oral bioavailability of hydrophilic macromolecules
US20030175346A1 (en) * 2002-02-01 2003-09-18 Anne Billotte Osmotic delivery system
US20030161882A1 (en) * 2002-02-01 2003-08-28 Waterman Kenneth C. Osmotic delivery system
US7004171B2 (en) * 2002-02-25 2006-02-28 Hi-Gienic Intra Vaginal Technologies Ltd. System for transvaginal drug delivery
ITMI20020515A1 (it) 2002-03-12 2003-09-12 Jagotec Ag Sistema per il rilasco controllato di uno o piu' principi attivi
ITMI20020514A1 (it) * 2002-03-12 2003-09-12 Jagotec Ag Sistema terapeutico per il rilascio controllato di uno o piu' principi attivi
DK2425821T5 (en) 2002-04-05 2018-02-12 Mundipharma As Pharmaceutical preparation containing oxycodone and naloxone
US20050106249A1 (en) * 2002-04-29 2005-05-19 Stephen Hwang Once-a-day, oral, controlled-release, oxycodone dosage forms
RU2004134594A (ru) * 2002-04-29 2005-06-27 Алза Корпорейшн (Us) Способы и лекарственные формы для контролируемой доставки оксикодона
US8871241B2 (en) 2002-05-07 2014-10-28 Psivida Us, Inc. Injectable sustained release delivery devices
AU2003241537A1 (en) * 2002-05-23 2003-12-12 Andrx Corporation Biguanide formulations
US7094427B2 (en) * 2002-05-29 2006-08-22 Impax Laboratories, Inc. Combination immediate release controlled release levodopa/carbidopa dosage forms
US20060013875A1 (en) * 2002-05-29 2006-01-19 Impax Laboratories, Inc. Combination immediate release controlled release levodopa/carbidopa dosage forms
US20040166159A1 (en) * 2002-05-29 2004-08-26 Chien-Hsuan Han Pharmaceutical dosage forms having immediate and controlled release properties that contain an aromatic amino acid decarboxylase inhibitor and levodopa
US20030224045A1 (en) * 2002-05-29 2003-12-04 Chien-Hsuan Han Combination immediate release sustained release levodopa/carbidopa dosage forms
MXPA04012021A (es) * 2002-05-31 2005-08-16 Johnson & Johnson Formas de dosis y composiciones para la administracion osmotica de dosis variables de oxicodona.
AR039744A1 (es) * 2002-06-26 2005-03-09 Alza Corp Metodos y formas de dosificacion para aumentar la solubilidad de las composiciones de farmacos para la administracion controlada
AR040306A1 (es) * 2002-06-28 2005-03-23 Alza Corp Capsula de liberacion controlada para la administracion de formulacion liquida
US20050232995A1 (en) * 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
WO2004010970A1 (en) * 2002-07-29 2004-02-05 Alza Corporation Formulations and dosage forms for controlled delivery of topiramate
US9060941B2 (en) * 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7785627B2 (en) * 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US20050048119A1 (en) * 2002-09-20 2005-03-03 Avinash Nangia Controlled release composition with semi-permeable membrane and poloxamer flux enhancer
US7959946B2 (en) 2002-09-20 2011-06-14 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US20050051922A1 (en) * 2002-09-20 2005-03-10 Avinash Nangia Pharmaceutical composition with sodium lauryl sulfate as an extra-granular absorption/compression enhancer and the process to make the same
JP4694841B2 (ja) 2002-09-20 2011-06-08 アンドルックス ラボズ リミテッド ライアビリティ カンパニー ビグアニドおよびチアゾリジンジオン誘導体を含有する多段階製剤
US20040091538A1 (en) * 2002-10-31 2004-05-13 Crystal Pollock-Dove Dosage form providing ascending release of liquid formulation
JP2006507309A (ja) * 2002-10-31 2006-03-02 アルザ・コーポレーシヨン 疎水性薬剤の上昇した生物学的利用性を提供する製剤
US6893660B2 (en) * 2002-11-21 2005-05-17 Andrx Pharmaceuticals, Inc. Stable pharmaceutical compositions without a stabilizer
AU2003299659A1 (en) 2002-12-13 2004-07-09 Durect Corporation Oral drug delivery system comprising high viscosity liquid carrier materials
US7259186B2 (en) * 2002-12-17 2007-08-21 Abbott Laboratories Salts of fenofibric acid and pharmaceutical formulations thereof
US20080051411A1 (en) * 2002-12-17 2008-02-28 Cink Russell D Salts of Fenofibric Acid and Pharmaceutical Formulations Thereof
EP1572190B1 (en) * 2002-12-17 2007-04-18 Abbott GmbH & Co. KG Formulation comprising fenofibric acid, a physiologically acceptable salt or derivative thereof
WO2004064772A2 (en) * 2003-01-14 2004-08-05 Alza Corporation Methods and dosage forms with modified viscosity layers
CA2515641A1 (en) * 2003-02-11 2004-08-26 Alza Corporation Methods and dosage forms with modified layer geometry
TWI347201B (en) * 2003-04-21 2011-08-21 Euro Celtique Sa Pharmaceutical products,uses thereof and methods for preparing the same
US7611480B2 (en) * 2003-04-24 2009-11-03 Levy Mark M Gastrointestinal bioreactor
AU2004249295A1 (en) * 2003-06-20 2004-12-29 Viral Genomix, Inc. Compositions for and methods for treating HIV
EP2112920B1 (en) 2003-06-26 2018-07-25 Intellipharmaceutics Corp. Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
EP1635875B8 (en) 2003-06-26 2008-12-24 pSivida Inc In-situ gelling drug delivery system
WO2005000268A2 (en) * 2003-06-26 2005-01-06 Control Delivery Systems, Inc. Bioerodible sustained release drug delivery systems
WO2005016306A2 (en) * 2003-08-06 2005-02-24 Alza Corporation Uniform delivery of topiramate over prolonged period of time with enhanced dispersion formulation
MXPA06002067A (es) * 2003-08-22 2006-08-11 Johnson & Johnson Suministro gradual de topiramato durante periodo prolongado.
EP1701697A2 (en) * 2003-09-02 2006-09-20 ALZA Corporation Novel drug compositions and dosage forms of topiramate
US7611728B2 (en) * 2003-09-05 2009-11-03 Supernus Pharmaceuticals, Inc. Osmotic delivery of therapeutic compounds by solubility enhancement
PL1663229T3 (pl) 2003-09-25 2010-09-30 Euro Celtique Sa Farmaceutyczne kombinacje hydrokodonu i naltreksonu
ATE544447T1 (de) 2003-09-26 2012-02-15 Alza Corp Arzneistoffcoating mit hohem wirkstoffanteil sowie methoden zu dessen herstellung
EP1680094A1 (en) * 2003-09-26 2006-07-19 Alza Corporation Controlled release formulations of opioid and nonopioid analgesics
EP1677769A1 (en) 2003-09-26 2006-07-12 Alza Corporation Controlled release formulations exhibiting an ascending rate of release
US20050260268A1 (en) * 2003-09-26 2005-11-24 Modi Nishit B Methods and dosage forms for controlled delivery of alprazolam
ES2287778T3 (es) * 2003-09-26 2007-12-16 Alza Corporation Forma de dosificacion de liberacion controlada mejorada que comprende un motor unido.
ATE504288T1 (de) * 2003-09-26 2011-04-15 Alza Corp Oros-push-stick für die kontrollierte abgabe von wirkstoffen
CA2540045A1 (en) * 2003-09-26 2005-04-07 Alza Corporation Dosage form for controlled release of an active agent formulation
JP2007509975A (ja) * 2003-10-31 2007-04-19 アルザ・コーポレーシヨン ギャバペンチン及びプレギャバリンの増加された吸収のための組成物及び投与形態物
US20050095288A1 (en) * 2003-11-03 2005-05-05 Andrx Labs, Llc Decongestant and expectorant tablets
KR20060120193A (ko) * 2003-11-14 2006-11-24 알자 코포레이션 액체 제형내 토피라메이트의 제어된 방출
WO2005051322A2 (en) * 2003-11-25 2005-06-09 Sb Pharmco Puerto Rico Inc. Controlled release pharmaceutical formulations comprising carvedilol, free based and its salts
JP2007512350A (ja) * 2003-11-25 2007-05-17 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド カルベジロール組成物の治療および送達方法
US20050129764A1 (en) * 2003-12-11 2005-06-16 Vergez Juan A. Osmotic device containing licofelone
KR20060123493A (ko) * 2003-12-23 2006-12-01 알자 코포레이션 제어된 전달을 위한 약물 조성물의 용해도를 증가시키는방법 및 제형
EP1701708A2 (en) * 2003-12-29 2006-09-20 Alza Corporation Novel drug compositions and dosage forms of topiramate
AU2004312082A1 (en) * 2003-12-29 2005-07-21 Alza Corporation, Inc. Novel drug compositions and dosage forms
US20050175696A1 (en) * 2003-12-29 2005-08-11 David Edgren Drug granule coatings that impart smear resistance during mechanical compression
AU2005210637B2 (en) 2004-01-30 2010-09-16 A.V. Topchiev Institute Of Petrochemical Synthesis Rapidly dissolving film for delivery of an active agent
WO2006079550A2 (en) * 2005-01-28 2006-08-03 Euro-Celtique S.A. Alcohol resistant dosage forms
US20050196448A1 (en) * 2004-03-05 2005-09-08 Hai Yong Huang Polymeric compositions and dosage forms comprising the same
US20050196442A1 (en) * 2004-03-05 2005-09-08 Huang Hai Y. Polymeric compositions and dosage forms comprising the same
US20050196447A1 (en) * 2004-03-05 2005-09-08 Huang Hai Y. Polymeric compositions and dosage forms comprising the same
US20050196446A1 (en) * 2004-03-05 2005-09-08 Huang Hai Y. Polymeric compositions and dosage forms comprising the same
TWI365880B (en) * 2004-03-30 2012-06-11 Euro Celtique Sa Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone and oxycodone hydrochloride composition,pharmaceutical dosage form,sustained release oeal dosage form and pharmaceutically acceptable package having less than 25 pp
US20060009425A1 (en) * 2004-05-28 2006-01-12 Leticia Delgado-Herrera Oral formulations of paricalcitol
EP1604667A1 (en) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the restless leg syndrome
EP1604666A1 (en) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
LT1765292T (lt) 2004-06-12 2018-01-10 Collegium Pharmaceutical, Inc. Nuo piktnaudžiavimo apsaugotos vaistų formos
US20050276848A1 (en) * 2004-06-15 2005-12-15 Nilobon Podhipleux Sustained release neutralized divalproex sodium
US7713550B2 (en) * 2004-06-15 2010-05-11 Andrx Corporation Controlled release sodium valproate formulation
US20050287185A1 (en) * 2004-06-23 2005-12-29 David Wong Extended release oxybutynin formulation
WO2006007323A2 (en) * 2004-06-28 2006-01-19 Alza Corporation Dosage forms for low solubility and/or low dissolution rate free acid pharmaceutical agents
WO2006007351A2 (en) * 2004-06-28 2006-01-19 Alza Corporation Squeeze controlled oral dosage form
EP1761265A2 (en) * 2004-06-28 2007-03-14 ALZA Corporation A drug/polymer complex, preferably ciprofloxacin/hpmc, its method of manufacturing using lyophilization and its use in an osmotic device
US8394409B2 (en) * 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
CA2511212A1 (en) * 2004-07-02 2006-01-02 Henkel Kommanditgesellschaft Auf Aktien Surface conditioner for powder coating systems
WO2006017807A2 (en) 2004-08-05 2006-02-16 Corium International, Inc. Adhesive composition
US20060057206A1 (en) * 2004-08-19 2006-03-16 Wong Patrick S Controlled release nanoparticle active agent formulation dosage forms and methods
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
US8541026B2 (en) * 2004-09-24 2013-09-24 Abbvie Inc. Sustained release formulations of opioid and nonopioid analgesics
US20070020330A1 (en) 2004-11-24 2007-01-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
US8758816B2 (en) * 2004-11-24 2014-06-24 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
EP2486942B1 (en) * 2004-11-24 2018-10-10 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
AR053986A1 (es) 2004-12-03 2007-05-30 Osmotica Pharmaceutical Argent Dispositivo osmotico que contiene amantadina y una sal osmotica
US8574626B2 (en) 2004-12-03 2013-11-05 Osmotica Kereskedelmi és Szolgáltató KFT Osmotic device containing amantadine and an osmotic salt
US8252331B2 (en) * 2004-12-03 2012-08-28 Osmotica Kereskedelmi és Szolgáltató, KFT Osmotic device containing amantadine and an osmotic salt
JP2008528629A (ja) * 2005-01-27 2008-07-31 アルザ・コーポレーシヨン 高流動性膜を有する経口浸透薬用量形態
EP1702558A1 (en) 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
EP1695700A1 (en) * 2005-02-28 2006-08-30 Euro-Celtique S.A. Dosage form containing oxycodone and naloxone
US7993667B2 (en) * 2005-03-25 2011-08-09 Kimberly-Clark Worldwide, Inc. Methods of manufacturing a medicated tampon assembly
US7919453B2 (en) * 2005-03-25 2011-04-05 Kimberly-Clark Worldwide, Inc. Dosage cap assembly for an applicator
US7744556B2 (en) * 2005-03-25 2010-06-29 Kimberly-Clark Worldwide, Inc. Delivery tube assembly for an applicator
US7527614B2 (en) 2005-03-25 2009-05-05 Kimberly-Clark Worldwide, Inc. Protective tube for a medicated tampon
US9295289B2 (en) * 2005-04-01 2016-03-29 Leslie Jane James Waist-fastening, hip-encompassing apparel with at least one concealed storage compartment
US20080152714A1 (en) * 2005-04-08 2008-06-26 Yi Gao Pharmaceutical Formulations
AU2006258217A1 (en) 2005-04-08 2006-12-21 Abbott Laboratories Oral pharmaceutical formulations comprising fenofibric acid and/or its salts
US20060233882A1 (en) * 2005-04-15 2006-10-19 Sowden Harry S Osmotic dosage form
JP2008536928A (ja) * 2005-04-19 2008-09-11 アルザ・コーポレーシヨン トラマドール及び、ガバペンチンを含んでなる物質、の組み合わせ物
US7708726B2 (en) * 2005-04-28 2010-05-04 Kimberly-Clark Worldwide, Inc. Dosage form cap for an applicator
AU2006261788B2 (en) 2005-06-27 2012-05-31 Valeant International Bermuda Modified-release formulations of a bupropion salt
WO2007002872A2 (en) * 2005-06-29 2007-01-04 Alza Corporation Semi-permeable compositions providing reduced drying time for osmotic dosage forms
WO2007019393A2 (en) * 2005-08-04 2007-02-15 Alza Corporation Osmotic dosage forms comprising semipermeable membranes with polymer blends providing improved properties
US20070036929A1 (en) * 2005-08-09 2007-02-15 The Boeing Company Thin film applique
BRPI0615410A2 (pt) * 2005-08-30 2013-02-13 Nicholas Piramal India Ltd composiÇço farmacÊutica de liberaÇço prolongada de metformina e processo para produÇço da mesma
US20070212397A1 (en) * 2005-09-15 2007-09-13 Roth Daniel B Pharmaceutical delivery device and method for providing ocular treatment
US8182840B2 (en) 2005-09-27 2012-05-22 Tissue Tech, Inc. Amniotic membrane preparations and purified compositions and therapy for scar reversal and inhibition
US8187639B2 (en) 2005-09-27 2012-05-29 Tissue Tech, Inc. Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment
US20070190137A1 (en) * 2005-10-07 2007-08-16 Reyes Iran Osmotic dosage form with controlled release and fast release aspects
US20070092559A1 (en) * 2005-10-24 2007-04-26 Jinghua Yuan Liquid dosage forms having enteric properties of delayed and then sustained release
PL116330U1 (en) * 2005-10-31 2007-04-02 Alza Corp Method for the reduction of alcohol provoked rapid increase in the released dose of the orally administered opioide with prolonged liberation
MX2008006888A (es) 2005-11-28 2008-09-30 Marinus Pharmaceuticals Formulas y metodos para la manufactura y uso de la ganaxolona.
US20070141118A1 (en) * 2005-12-15 2007-06-21 Damico Joyce A Layered dosage form for a medicated tampon assembly
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
US20100172989A1 (en) * 2006-01-21 2010-07-08 Abbott Laboratories Abuse resistant melt extruded formulation having reduced alcohol interaction
US20090317355A1 (en) * 2006-01-21 2009-12-24 Abbott Gmbh & Co. Kg, Abuse resistant melt extruded formulation having reduced alcohol interaction
US20090022798A1 (en) * 2007-07-20 2009-01-22 Abbott Gmbh & Co. Kg Formulations of nonopioid and confined opioid analgesics
EP1813276A1 (en) * 2006-01-27 2007-08-01 Euro-Celtique S.A. Tamper resistant dosage forms
US20070196487A1 (en) * 2006-02-16 2007-08-23 Geerke Johan H Method and apparatus for drilling orifices in osmotic tablets incorporating near-infrared spectroscopy
CA2646023A1 (en) 2006-03-10 2007-09-20 Neurogen Corporation Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues
US20190083399A9 (en) * 2006-04-03 2019-03-21 Isa Odidi Drug delivery composition
CA2648280C (en) * 2006-04-03 2014-03-11 Isa Odidi Controlled release delivery device comprising an organosol coat
US8747897B2 (en) 2006-04-27 2014-06-10 Supernus Pharmaceuticals, Inc. Osmotic drug delivery system
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
ATE510538T1 (de) 2006-08-11 2011-06-15 Univ Johns Hopkins Zusammensetzungen und verfahren für nervenschutz
US7538652B2 (en) * 2006-08-29 2009-05-26 International Business Machines Corporation Electrical component tuned by conductive layer deletion
EP1897543A1 (en) 2006-08-30 2008-03-12 Euro-Celtique S.A. Buprenorphine- wafer for drug substitution therapy
SG166093A1 (en) 2006-09-22 2010-11-29 Pharmacyclics Inc Inhibitors of brutonæs tyrosine kinase
AU2007325780B9 (en) 2006-11-27 2013-09-12 H. Lundbeck A/S Heteroaryl amide derivatives
AU2007325628A1 (en) 2006-11-28 2008-06-05 Marinus Pharmaceuticals Nanoparticulate formulations and methods for the making and use thereof
JPWO2008084698A1 (ja) 2006-12-28 2010-04-30 アステラス製薬株式会社 タクロリムス徐放性医薬組成物
US8524749B2 (en) * 2007-02-09 2013-09-03 Alza Corporation Controlled release compositions of tizanidine
US8895061B2 (en) * 2007-03-02 2014-11-25 Meda Pharmaceuticals Inc. Compositions comprising carisoprodol and methods of use thereof
US20080064701A1 (en) * 2007-04-24 2008-03-13 Ramesh Sesha Anti-diabetic combinations
US20070172525A1 (en) * 2007-03-15 2007-07-26 Ramesh Sesha Anti-diabetic combinations
WO2008116004A2 (en) 2007-03-19 2008-09-25 Vita Sciences, Llc Transdermal patch and method for delivery of vitamin b12
US20090082315A1 (en) * 2007-09-05 2009-03-26 Raif Tawakol Compositions and Methods for Controlling Cholesterol Levels
CN101854933A (zh) 2007-09-10 2010-10-06 钙医学公司 调节细胞内钙的化合物
US20090087484A1 (en) * 2007-09-28 2009-04-02 Alza Corporation Formulation and dosage form for increasing oral bioavailability of hydrophilic macromolecules
EP2219633A2 (en) 2007-11-23 2010-08-25 Nectid, Inc. Tapentadol compositions
CA2706931C (en) 2007-12-06 2015-05-12 Durect Corporation Oral pharmaceutical dosage forms
US9226907B2 (en) 2008-02-01 2016-01-05 Abbvie Inc. Extended release hydrocodone acetaminophen and related methods and uses thereof
US8551524B2 (en) * 2008-03-14 2013-10-08 Iycus, Llc Anti-diabetic combinations
CN102027133A (zh) * 2008-05-07 2011-04-20 温瑟瑞克斯有限公司 鉴定调节癌细胞中Wnt信号传导的化合物的方法
WO2009137631A2 (en) * 2008-05-07 2009-11-12 Wintherix Llc Methods for identifying compounds that affect expression of cancer-related protein isoforms
US8173637B2 (en) * 2008-07-24 2012-05-08 Handa Pharmaceuticals, Llc Stabilized atypical antipsychotic formulation
US7906553B2 (en) 2008-08-27 2011-03-15 Calcimedica, Inc. Substituted thiophene modulators of intracellular calcium
US20100190752A1 (en) 2008-09-05 2010-07-29 Gruenenthal Gmbh Pharmaceutical Combination
EP2163240A1 (en) 2008-09-12 2010-03-17 Universita' Degli Studi Di Genova A method for the production of bioadhesive compact matrices
MX2011004455A (es) 2008-10-30 2011-05-25 Gruenenthal Gmbh Formas de dosificacion del tapentadol novedosas y potentes.
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
US20100233259A1 (en) * 2008-12-12 2010-09-16 Pascal Grenier Dosage form of ropinirole
WO2010071866A2 (en) 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Combination therapy for arthritis with tranilast
CA2751884C (en) 2009-01-14 2018-09-25 Corium International, Inc. Transdermal administration of tamsulosin
AU2010208046B2 (en) * 2009-01-29 2014-10-02 Forsight Vision4, Inc. Posterior segment drug delivery
US8623395B2 (en) 2010-01-29 2014-01-07 Forsight Vision4, Inc. Implantable therapeutic device
CA2749933A1 (en) * 2009-02-04 2010-08-12 Supernus Pharmaceuticals, Inc. Formulations of desvenlafaxine
EP2448406B1 (en) 2009-02-26 2016-04-20 Relmada Therapeutics, Inc. Extended release oral pharmaceutical compositions of 3-hydroxy-n-methylmorphinan and method of use
AR075735A1 (es) 2009-03-10 2011-04-20 Euro Celtique Sa Composiciones farmaceuticas de liberacion inmediata que comprenden oxicodona y naloxona. uso
CA2758571A1 (en) 2009-04-24 2010-10-28 Tissuetech, Inc. Compositions containing hc-ha complex and methods of use thereof
WO2010139111A1 (en) 2009-06-02 2010-12-09 Dow Global Technologies Inc. Sustained release dosage form
US7741330B1 (en) 2009-10-12 2010-06-22 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
JP2013515741A (ja) * 2009-12-23 2013-05-09 サイヴィーダ ユーエス，インコーポレイテッド 持続放出性送達デバイス
EP2534145A4 (en) 2010-02-08 2013-09-11 Kinagen Inc THERAPEUTIC METHODS AND COMPOSITIONS INVOLVING THE INHIBITION OF ALLOSTERIC KINASE
KR101844088B1 (ko) 2010-03-24 2018-03-30 아미텍 테러퓨틱 솔루션즈 인크 인산화효소 억제에 유용한 헤테로환 화합물
US20120070465A1 (en) 2010-03-29 2012-03-22 Astellas Pharma Inc. Pharmaceutical composition for modified release
KR20130073893A (ko) 2010-04-13 2013-07-03 나지브 바불 1-메틸-2''-6''-피페콜옥실리디드의 피부 약제학적 조성물 및 사용 방법
EP2558866B1 (en) 2010-04-15 2016-08-17 Tracon Pharmaceuticals, Inc. Potentiation of anti-cancer activity through combination therapy with ber pathway inhibitors
PL2563776T3 (pl) 2010-04-27 2017-01-31 Calcimedica Inc Związki, które modulują wewnątrzkomórkowy wapń
CA2797533A1 (en) 2010-04-27 2011-11-10 Calcimedica, Inc. Compounds that modulate intracellular calcium
EP2568999B1 (en) 2010-05-11 2018-07-11 Mallinckrodt Ard Ip Limited Acth for treatment of amyotrophic lateral sclerosis
NZ717373A (en) 2010-06-03 2017-11-24 Pharmacyclics Llc The use of inhibitors of bruton’s tyrosine kinase (btk)
US20120009261A1 (en) 2010-07-06 2012-01-12 Grünenthal GmbH Novel gastro-retentive dosage forms
WO2012007159A2 (en) 2010-07-14 2012-01-19 Grünenthal GmbH Novel gastro-retentive dosage forms
HUE054113T2 (hu) 2010-08-05 2021-08-30 Forsight Vision4 Inc Injekciós készülék gyógyszerbejuttatáshoz
HRP20211909T1 (hr) 2010-08-05 2022-03-18 Forsight Vision4, Inc. Uređaj za liječenja oka
EP2600876B1 (en) 2010-08-05 2015-04-29 Forsight Vision4, Inc. Combined drug delivery methods and apparatus
WO2012027710A2 (en) 2010-08-27 2012-03-01 Calcimedica Inc. Compounds that modulate intracellular calcium
US8796416B1 (en) 2010-10-25 2014-08-05 Questcor Pharmaceuticals, Inc ACTH prophylactic treatment of renal disorders
US20140031769A1 (en) 2010-11-19 2014-01-30 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
AP3815A (en) 2010-12-22 2016-09-30 Purdue Pharma Lp Encased tamper resistant controlled release dosage forms
PH12013501345A1 (en) 2010-12-23 2022-10-24 Purdue Pharma Lp Tamper resistant solid oral dosage forms
PH12013501427B1 (en) 2011-01-07 2019-02-13 Allergan Inc Melanin modification compositions and methods of use
WO2012149486A1 (en) 2011-04-28 2012-11-01 Tissuetech, Inc. Methods of modulating bone remodeling
CA2837878A1 (en) 2011-06-10 2012-12-13 Tissuetech, Inc. Methods of processing fetal support tissues, fetal support tissue powder products, and uses thereof
US10398592B2 (en) 2011-06-28 2019-09-03 Forsight Vision4, Inc. Diagnostic methods and apparatus
EP2739252A4 (en) 2011-08-05 2015-08-12 Forsight Vision4 Inc SMALL MOLECULE ADMINISTRATION USING AN IMPLANTABLE THERAPEUTIC DEVICE
EP4643921A2 (en) 2011-09-16 2025-11-05 ForSight Vision4, Inc. Fluid exchange apparatus
US20130090633A1 (en) * 2011-10-07 2013-04-11 University Of Southern California Osmotic patch pump
CA2795586A1 (en) 2011-11-15 2013-05-15 Golden Biotechnology Corporation Methods and compositions for treatment, modification and management of bone cancer pain
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
CA2800329A1 (en) 2011-12-30 2013-06-30 Golden Biotechnology Corporation Methods and compositions for treating diabetes
US10010448B2 (en) 2012-02-03 2018-07-03 Forsight Vision4, Inc. Insertion and removal methods and apparatus for therapeutic devices
FR2987264A1 (fr) 2012-02-23 2013-08-30 Golden Biotechnology Corp Methodes et compositions pour le traitement des metastases cancereuses
BR112014023809A2 (pt) 2012-03-26 2017-07-18 Golden Biotechnology Corp métodos e composições para o tratamento de doenças vasculares ateroscleróticas
US10040821B2 (en) 2012-07-11 2018-08-07 Tissuetech, Inc. Compositions containing HC-HA/PTX3 complexes and methods of use thereof
UA117226C2 (uk) 2012-07-16 2018-07-10 Родес Текнолоджіс Спосіб покращеного синтезу опіоїду
US10316042B2 (en) 2012-07-16 2019-06-11 Rhodes Technologies Process for improved opioid synthesis
US9512116B2 (en) 2012-10-12 2016-12-06 Calcimedica, Inc. Compounds that modulate intracellular calcium
CN104968339B (zh) 2012-11-21 2019-06-11 国鼎生物科技股份有限公司 用于治疗神经变性疾病的方法和组合物
PE20151301A1 (es) 2013-02-05 2015-09-16 Purdue Pharma Lp Formulaciones farmaceuticas resistentes a la manipulacion indebida
TWI597061B (zh) 2013-02-20 2017-09-01 國鼎生物科技股份有限公司 治療白血病之方法及組成物
EP2968113B8 (en) 2013-03-14 2020-10-28 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
EP2968475A2 (en) 2013-03-14 2016-01-20 Questcor Pharmaceuticals, Inc. Acth for treatment of acute respiratory distress syndrome
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
CN105120659A (zh) 2013-03-15 2015-12-02 度瑞公司 用于降低溶解可变性的具有流变改性剂的组合物
CN105246438B (zh) 2013-03-28 2018-01-26 弗赛特影像4股份有限公司 用于输送治疗物质的眼科植入物
RU2015151175A (ru) 2013-04-30 2017-06-07 Эббви, Инк. Способы улучшения липидных профилей с применением атрасентана
WO2015011189A1 (en) 2013-07-23 2015-01-29 Euro-Celtique S.A. A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
ES2823000T3 (es) 2013-10-07 2021-05-05 Impax Laboratories Llc Formulaciones muco-adhesivas de liberación controlada de levodopa y/o ésteres de levodopa y usos de las mismas
US10987313B2 (en) 2013-10-07 2021-04-27 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
WO2015054283A1 (en) 2013-10-08 2015-04-16 Calcimedica, Inc. Compounds that modulate intracellular calcium
MX375752B (es) 2013-12-05 2025-03-06 Pharmacyclics Llc Inhibidores de tirosina quinasa de bruton.
CN106029670A (zh) 2014-01-15 2016-10-12 罗德科技公司 改进的羟考酮合成的方法
CN106029669B (zh) 2014-01-15 2018-04-13 罗德科技公司 改进的羟二氢吗啡酮合成的方法
CA2938996A1 (en) 2014-02-10 2015-08-13 Patara Pharma, LLC Methods for the treatment of lung diseases with mast cell stabilizers
US9962363B2 (en) 2014-02-10 2018-05-08 Patara Pharma, LLC Mast cell stabilizers treatment for systemic disorders
EP3134418A4 (en) 2014-04-23 2018-01-03 The Research Foundation for The State University of New York A rapid and efficient bioorthogonal ligation reaction and boron-containing heterocycles useful in conjuction therewith
TW201603818A (zh) 2014-06-03 2016-02-01 組織科技股份有限公司 組成物及方法
EP3169289B1 (en) 2014-07-15 2020-04-15 ForSight Vision4, Inc. Ocular implant delivery device
MX2017001818A (es) 2014-08-08 2017-05-30 Forsight Vision4 Inc Formulaciones estables y solubles de inhibidores de receptor de quinasa tirosina y metodos de preparacion de los mismos.
US9839644B2 (en) 2014-09-09 2017-12-12 ARKAY Therapeutics, LLC Formulations and methods for treatment of metabolic syndrome
MX383085B (es) 2014-11-10 2025-03-13 Forsight Vision4 Inc Dispositivo de entrega de fármacos expandibles y método de uso.
US9359316B1 (en) 2014-11-25 2016-06-07 Concentric Analgesics, Inc. Prodrugs of phenolic TRPV1 agonists
US10227333B2 (en) 2015-02-11 2019-03-12 Curtana Pharmaceuticals, Inc. Inhibition of OLIG2 activity
WO2016132233A1 (en) 2015-02-20 2016-08-25 Osmotica Kereskedelmi Es Szolgaltato Kft Controlled release oral dosage form of gaba receptor agonist with enhanced pharmacokinetics
TW201642914A (zh) 2015-02-23 2016-12-16 組織科技股份有限公司 用於治療眼部疾病及失調的裝置及方法
AU2016225000B2 (en) 2015-02-27 2021-04-01 Curtana Pharmaceuticals, Inc. Inhibition of Olig2 activity
EP3061501A1 (en) 2015-02-27 2016-08-31 Rottapharm Ltd. Composition for the treatment of acne
HK1250940A1 (zh) 2015-05-20 2019-01-18 Tissuetech, Inc. 用於预防上皮细胞的增殖和上皮-间充质转换的组合物和方法
EP3117825A1 (en) 2015-07-16 2017-01-18 Rottapharm S.p.A. Oral formulation comprising berberine and morus alba extract
US10238625B2 (en) 2015-08-07 2019-03-26 Respivant Sciences Gmbh Methods for the treatment of mast cell related disorders with mast cell stabilizers
WO2017027402A1 (en) 2015-08-07 2017-02-16 Patara Pharma, LLC Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
AU2016317049A1 (en) 2015-08-31 2018-03-15 Pharmacyclics Llc BTK inhibitor combinations for treating multiple myeloma
CA3005238A1 (en) 2015-11-20 2017-05-26 Forsight Vision4, Inc. Porous structures for extended release drug delivery devices
WO2017132410A1 (en) 2016-01-26 2017-08-03 Frank Litvack Compositions and uses of alpha-adrenergic agents
TW201733600A (zh) 2016-01-29 2017-10-01 帝聖工業公司 胎兒扶持組織物及使用方法
US10851123B2 (en) 2016-02-23 2020-12-01 Concentric Analgesics, Inc. Prodrugs of phenolic TRPV1 agonists
KR20180133440A (ko) 2016-04-05 2018-12-14 포사이트 비젼4, 인크. 이식 가능한 안구 약물 전달 장치
JP2019516700A (ja) 2016-05-12 2019-06-20 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Ａｓｈ１ｌ阻害剤及びそれを用いた治療方法
CN109562281B (zh) 2016-05-25 2021-12-17 同心镇痛药物公司 酚类trpv1激动剂的前药与局部麻醉药和血管收缩剂联合用于改善局部麻醉
WO2017205769A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
WO2017205766A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
WO2017205762A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
WO2017222575A1 (en) 2016-06-23 2017-12-28 Collegium Pharmaceutical, Inc. Process of making more stable abuse-deterrent oral formulations
AU2017292791B2 (en) 2016-07-06 2023-05-25 Orient Pharma Co., Ltd. Oral dosage form with drug composition, barrier layer and drug layer
CN106317468A (zh) * 2016-08-23 2017-01-11 无锡市永亿精密铸造有限公司 一种用于超声波美容仪的复合材料
KR102605329B1 (ko) 2016-08-26 2023-11-22 커타나 파마슈티칼스, 인크. Olig2 활성의 억제
EP3506893A4 (en) 2016-08-31 2020-01-22 Respivant Sciences GmbH CROMOLYN COMPOSITIONS FOR THE TREATMENT OF CHRONIC COUGH DUE TO IDIOPATHIC PULMONAL FIBROSIS
US10736905B1 (en) 2016-09-09 2020-08-11 Shahin Fatholahi Nefopam dosage forms and methods of treatment
AU2017339366A1 (en) 2016-10-07 2019-04-11 Respivant Sciences Gmbh Cromolyn compositions for treatment of pulmonary fibrosis
US11446311B2 (en) 2017-09-08 2022-09-20 Shahin Fatholahi Methods for treating pain associated with sickle cell disease
US10736874B1 (en) 2017-09-08 2020-08-11 Shahin Fatholahi Methods for treating pain associated with sickle cell disease
CA3082077A1 (en) 2017-11-10 2019-05-16 The Regents Of The University Of Michigan Ash1l degraders and methods of treatment therewith
AU2018372806B2 (en) 2017-11-21 2024-05-30 Forsight Vision4, Inc. Fluid exchange apparatus for expandable port delivery system and methods of use
AU2018378935B2 (en) 2017-12-07 2024-10-31 The Regents Of The University Of Michigan NSD family inhibitors and methods of treatment therewith
US10213394B1 (en) 2018-02-15 2019-02-26 Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság Composition and method for treating neurological disease
US20190247331A1 (en) 2018-02-15 2019-08-15 Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság Composition and method for treating neurological disease
US10213393B1 (en) 2018-02-15 2019-02-26 Osmotica Kereskedelmi és Szolgáltató Korlátolt Feleõsségû Társaság Composition and method for treating neurological disease
CN111971030A (zh) 2018-02-16 2020-11-20 艾斯柏伦治疗公司 贝派地酸的缓释制剂
WO2019169112A1 (en) 2018-02-28 2019-09-06 Curtana Pharmaceuticals, Inc. Inhibition of olig2 activity
EP3813784B1 (en) 2018-06-07 2024-01-10 The Regents Of The University Of Michigan Prc1 inhibitors and prc1 inhibitors for use in methods of treatment therewith
US10717712B2 (en) 2018-07-27 2020-07-21 Concentric Analgesics, Inc. Pegylated prodrugs of phenolic TRPV1 agonists
AU2019417833B2 (en) 2018-12-31 2024-11-07 Biomea Fusion, Inc. Irreversible inhibitors of menin-MLL interaction
US12377082B2 (en) 2019-03-15 2025-08-05 Unicycive Therapeutics Inc. Nicorandil derivatives
KR20230008711A (ko) 2020-05-08 2023-01-16 골든 바이오테크놀러지 코포레이션 Rna 바이러스 유도된 질환을 치료하기 위한 방법 및 조성물
US11858925B2 (en) 2020-07-10 2024-01-02 The Regents Of The University Of Michigan GAS41 inhibitors and methods of use thereof
US20240124467A1 (en) 2020-12-16 2024-04-18 Biomea Fusion, Inc. Fused pyrimidine compounds as inhibitors of menin-mll interaction
JP2024501235A (ja) 2020-12-22 2024-01-11 アムニール ファーマスーティカルズ エルエルシー レボドパ投薬レジメン
US11986449B2 (en) 2020-12-22 2024-05-21 Amneal Pharmaceuticals Llc Levodopa dosing regimen
CA3228627A1 (en) 2021-08-11 2023-02-16 Thomas Butler Covalent inhibitors of menin-mll interaction for diabetes mellitus
WO2023027966A1 (en) 2021-08-24 2023-03-02 Biomea Fusion, Inc. Pyrazine compounds as irreversible inhibitors of flt3
US20240409558A1 (en) 2021-09-13 2024-12-12 Biomea Fusion, Inc. Irreversible inhibitors of kras
WO2023086341A1 (en) 2021-11-09 2023-05-19 Biomea Fusion, Inc. Inhibitors of kras
WO2023119230A1 (en) 2021-12-22 2023-06-29 L'oreal Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use
PE20242008A1 (es) 2021-12-30 2024-10-03 Biomea Fusion Inc Compuestos de pirazina como inhibidores de flt3
USD1033637S1 (en) 2022-01-24 2024-07-02 Forsight Vision4, Inc. Fluid exchange device
US20250353854A1 (en) 2022-06-03 2025-11-20 Biomea Fusion, Inc. Fused pyrimidine compounds as inhibitors of menin
WO2024243402A2 (en) 2023-05-24 2024-11-28 Unicycive Therapeutics Inc. Salt forms of nicorandil derivatives
WO2024249950A1 (en) 2023-06-02 2024-12-05 Biomea Fusion, Inc. Fused pyrimidine compounds as inhibitors of menin
WO2025034784A1 (en) 2023-08-08 2025-02-13 United Therapeutics Corporation A method of producing an oral osmotic pharmaceutical delivery system and a pharmaceutical batch produced using the same
US20250145571A1 (en) 2023-09-26 2025-05-08 Unicycive Therapeutics, Inc. Amino acid prodrugs of nicorandil
WO2025194102A1 (en) 2024-03-15 2025-09-18 Unicycive Therapeutics, Inc. Pyridine modified nicorandil derivatives
WO2025208111A1 (en) 2024-03-29 2025-10-02 Biomea Fusion, Inc. Heterocyclic glp-1r agonists

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3129159A (en) * 1961-09-29 1964-04-14 Membranfiltergesellschaft G M Process for manufacturing membranes
US3497072A (en) * 1966-05-02 1970-02-24 Aerojet General Co Reverse osmosis membrane and method of manufacture
US3460683A (en) * 1966-08-22 1969-08-12 Aerojet General Co Cellulose acetate membranes
US3567809A (en) * 1966-10-07 1971-03-02 Fuji Photo Film Co Ltd Method of varying the pore diameters of fine pores in cellulose acetate film
US3522335A (en) * 1968-02-29 1970-07-28 Eastman Kodak Co Methods for producing reverse osmosis membrane and the composition utilized
US3607329A (en) * 1969-04-22 1971-09-21 Us Interior Cellulose acetate butyrate semipermeable membranes and their production
US3593855A (en) * 1969-05-13 1971-07-20 Westinghouse Electric Corp High flow porous reverse osmosis membranes containing lipids
US3646179A (en) * 1969-05-22 1972-02-29 Westinghouse Electric Corp Process for preparing high pressure cellulose acetate semipermeable membranes
US3592672A (en) * 1969-12-22 1971-07-13 Eastman Kodak Co Dry stabilized,rewettable semipermeable cellulose ester and ether membranes and their preparation
US3592671A (en) * 1969-12-22 1971-07-13 Eastman Kodak Co Stabilization of cellulose ester dopes
US3760806A (en) * 1971-01-13 1973-09-25 Alza Corp Helical osmotic dispenser with non-planar membrane
SE352811B (enExample) * 1971-06-04 1973-01-15 Pharmacia Ab
US3772072A (en) * 1971-06-14 1973-11-13 Eastman Kodak Co Method for treating reverse osmosis membranes
US3721623A (en) * 1971-07-23 1973-03-20 Westinghouse Electric Corp Method of improving the salt rejection of semipermeable reverse osmosis membranes
US3938515A (en) * 1971-12-20 1976-02-17 Alza Corporation Novel drug permeable wall
GB1388034A (en) * 1972-04-12 1975-03-19 Atomic Energy Authority Uk Membranes for reverse osmosis
US3878276A (en) * 1972-05-24 1975-04-15 Us Interior Cellulose acetate blend membranes
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3875300A (en) * 1972-12-18 1975-04-01 Ortho Pharma Corp Composition for sustained release of a medicament and method of using same
US3929132A (en) * 1973-04-10 1975-12-30 Alza Corp Osmotic dispenser
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4077407A (en) * 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls

Also Published As

Publication number Publication date
US4160020A (en) 1979-07-03
DK150533C (da) 1987-10-12
DK150533B (da) 1987-03-23
DK519276A (da) 1977-05-25
CH629957A5 (de) 1982-05-28
JPS6058724B2 (ja) 1985-12-21
ATA854676A (de) 1979-10-15
FR2332008B1 (enExample) 1979-03-09
IT1070481B (it) 1985-03-29
NL187298C (nl) 1991-08-16
BE848639A (fr) 1977-03-16
IL50851A0 (en) 1977-01-31
US4077407A (en) 1978-03-07
FR2332008A1 (fr) 1977-06-17
AT356821B (de) 1980-05-27
MX157537A (es) 1988-11-29
NL187298B (nl) 1991-03-18
JPS5264419A (en) 1977-05-27
DE2653232A1 (de) 1977-06-08
SE7613035L (sv) 1977-05-25
SE430301B (sv) 1983-11-07
CA1074653A (en) 1980-04-01
IE44264L (en) 1977-05-24
ES453530A1 (es) 1977-12-01
IL50851A (en) 1979-11-30
AR216642A1 (es) 1980-01-15
ZA766900B (en) 1977-10-26
IE44264B1 (en) 1981-09-23
AU506506B2 (en) 1980-01-10
GB1528265A (en) 1978-10-11
NL7613110A (nl) 1977-05-26
AU1980276A (en) 1978-05-25

Similar Documents

Publication Publication Date Title
DE2653232C2 (enExample)
DE2814709C2 (enExample)
DE3486409T2 (de) Zusammensetzung zur kontrollierten Abgabe eines Wirkstoffs.
DE2751587C2 (de) Durch Osmose wirksame Vorrichtung zur Abgabe eines Arzneimittels und Verfahren zu deren Herstellung
AT402689B (de) Dosierungsform für die behandlung kardiovaskulärererkrankungen
DE3687799T2 (de) Osmotische pumpe fuer lipide.
DE69212710T2 (de) Pharmazeutische Zusammensetzung mit kontrollierter Freigabe und bioadhäsiven Eigenschaften
DE3015870C2 (de) Vorrichtung zur Abgabe eines Wirkstoffs durch Diffusion
DE2640193C2 (de) Vorrichtung zur Abgabe eines Wirkstoffs durch Osmose und Verfahren zu deren Herstellung
DE69107461T2 (de) Verwendung von interfacial polymerisierten membranen in abgabevorrichtungen.
US4483846A (en) Long-lasting three-layered pharmaceutical film preparations
DE3821426A1 (de) Abgabesystem aus mehreren schichten
DE2336218B2 (de) Neue orale Arzneiform und Verfahren zu ihrer Herstellung
AT396329B (de) Pharmazeutische granulate und verfahren zu ihrer herstellung
CH663352A5 (de) Osmotische kapsel.
DE3725824A1 (de) Orales therapeutisches system mit systemischer wirkung
DE3613433A1 (de) Osmotische abgabevorrichtung
DE2648737A1 (de) Augeneinsaetze zur behandlung von wassermangel am auge
DE60019334T2 (de) Antivirale arznei
DE2709356A1 (de) Durch osmose wirksame vorrichtung zur abgabe eines wirkstoffs
CH666415A5 (de) System zur kontrollierten abgabe eines darin enthaltenen biologisch aktiven mittels aus einer polymer-matrix.
DE3626362A1 (de) Abgabevorrichtung zur freisetzung eines wirkstoffs an wiederkaeuer
DE69928815T2 (de) Dosierungsform mit flüssiger formulierung
DE68907177T2 (de) Dosierungsform.
CH659584A5 (de) Wirkstoffspender mit aus einem semipermeablen bestandteil und einem magensaftresistenten bestandteil gebildeter wand.

Legal Events

Date Code Title Description
8110 Request for examination paragraph 44
8125 Change of the main classification

Ipc: B01J 4/04

D2 Grant after examination
8364 No opposition during term of opposition